CUMYL-CBMINACA

CUMYL-CBMINACA
Legal status
Legal status	DE: NpSG (Industrial and scientific use only); UK: Class B;
Identifiers
	IUPAC name 1-(cyclobutylmethyl)-N-(2-phenylpropan-2-yl)indazole-3-carboxamide;
ChemSpider	90606548;
Chemical and physical data
Formula	C22H25N3O
Molar mass	347.462 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(NC(=O)c3nn(CC1CCC1)c2ccccc23)c4ccccc4;
	InChI InChI=1S/C22H25N3O/c1-22(2,17-11-4-3-5-12-17)23-21(26)20-18-13-6-7-14-19(18)25(24-20)15-16-9-8-10-16/h3-7,11-14,16H,8-10,15H2,1-2H3,(H,23,26); Key:CFMZQSDQCNKGII-UHFFFAOYSA-N;

CUMYL-CBMINACA (SGT-277) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first being identified in Germany in February 2020.^[1]

References

^ "EU Early Warning System Situation Report. Situation report 1" (PDF). European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). June 2020.

This cannabinoid related article is a stub. You can help Wikipedia by expanding it.

[1] "EU Early Warning System Situation Report. Situation report 1" (PDF). European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). June 2020.

[1]

See also

References